Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)
Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –
Actinium Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Actinium Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.12M, down 33.3% year over year. For fiscal 2025 it was $21.12M, down 29.7% from the year before. Over ten years it grew 4.6% a year on average. The highest annual figure on record is $38.67M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.12M | -29.7% |
| FY2024 | Dec 31, 2024 | $30.05M | -22.3% |
| FY2023 | Dec 31, 2023 | $38.67M | +67.1% |
| FY2022 | Dec 31, 2022 | $23.14M | +28.3% |
| FY2021 | Dec 31, 2021 | $18.03M | +12.1% |
| FY2020 | Dec 31, 2020 | $16.09M | -2.8% |
| FY2019 | Dec 31, 2019 | $16.55M | -3.2% |
| FY2018 | Dec 31, 2018 | $17.09M | -3.5% |
| FY2017 | Dec 31, 2017 | $17.72M | -0.6% |
| FY2016 | Dec 31, 2016 | $17.83M | +32.0% |
| FY2015 | Dec 31, 2015 | $13.50M | +10.1% |
| FY2014 | Dec 31, 2014 | $12.27M | +294.5% |
| FY2013 | Dec 31, 2013 | $3.11M | -9.6% |
| FY2012 | Dec 31, 2012 | $3.44M | +962.6% |
| FY2011 | Dec 31, 2011 | $323.79K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.38M | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.20M | -45.4% |
| Q4 FY2025 | Dec 31, 2025 | $4.30M | -10.7% |
| Q3 FY2025 | Sep 30, 2025 | $4.25M | -56.5% |
| Q2 FY2025 | Jun 30, 2025 | $4.88M | -44.7% |
| Q1 FY2025 | Mar 31, 2025 | $7.70M | +16.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.81M | -40.7% |
| Q3 FY2024 | Sep 30, 2024 | $9.77M | -15.9% |
| Q2 FY2024 | Jun 30, 2024 | $8.83M | -20.4% |
| Q1 FY2024 | Mar 31, 2024 | $6.64M | -15.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.12M | +10.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.62M | +71.6% |
| Q2 FY2023 | Jun 30, 2023 | $11.08M | +137.7% |
| Q1 FY2023 | Mar 31, 2023 | $7.85M | +79.7% |
| Q4 FY2022 | Dec 31, 2022 | $7.33M | +35.4% |
| Q3 FY2022 | Sep 30, 2022 | $6.77M | +43.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.66M | +28.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.37M | +2.2% |
| Q4 FY2021 | Dec 31, 2021 | $5.42M | +16.7% |
| Q3 FY2021 | Sep 30, 2021 | $4.71M | +24.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.63M | +3.5% |
| Q1 FY2021 | Mar 31, 2021 | $4.28M | +3.0% |
| Q4 FY2020 | Dec 31, 2020 | $4.64M | +37.5% |
| Q3 FY2020 | Sep 30, 2020 | $3.79M | -21.6% |
| Q2 FY2020 | Jun 30, 2020 | $3.51M | -12.5% |
| Q1 FY2020 | Mar 31, 2020 | $4.15M | -4.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.37M | -33.5% |
| Q3 FY2019 | Sep 30, 2019 | $4.83M | +14.3% |
| Q2 FY2019 | Jun 30, 2019 | $4.01M | +20.4% |
| Q1 FY2019 | Mar 31, 2019 | $4.34M | -2.9% |
| Q4 FY2018 | Dec 31, 2018 | $5.07M | +38.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.23M | -15.9% |
| Q2 FY2018 | Jun 30, 2018 | $3.33M | -25.1% |
| Q1 FY2018 | Mar 31, 2018 | $4.47M | -2.3% |
| Q4 FY2017 | Dec 31, 2017 | $3.67M | -13.2% |
| Q3 FY2017 | Sep 30, 2017 | $5.03M | -11.6% |
| Q2 FY2017 | Jun 30, 2017 | $4.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.57M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.23M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.69M | – |
See a number that looks wrong?